Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase

Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs or dialysis-dependent end-stage renal disease. The study aims to compare prophylaxis with fondaparinux (Fund) vs. treatment with alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male m...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed S. Abdel-Bakky (Author), Anas S. A. Aldakhili (Author), Hussein M. Ali (Author), Ali Y. Babiker (Author), Ahmad H. Alhowail (Author), Salman A. A. Mohammed (Author)
Format: Book
Published: MDPI AG, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1f634f05d36e43f4906cde7397b5a4c7
042 |a dc 
100 1 0 |a Mohamed S. Abdel-Bakky  |e author 
700 1 0 |a Anas S. A. Aldakhili  |e author 
700 1 0 |a Hussein M. Ali  |e author 
700 1 0 |a Ali Y. Babiker  |e author 
700 1 0 |a Ahmad H. Alhowail  |e author 
700 1 0 |a Salman A. A. Mohammed  |e author 
245 0 0 |a Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase 
260 |b MDPI AG,   |c 2023-06-01T00:00:00Z. 
500 |a 10.3390/ph16070910 
500 |a 1424-8247 
520 |a Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs or dialysis-dependent end-stage renal disease. The study aims to compare prophylaxis with fondaparinux (Fund) vs. treatment with alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male mice were equally divided randomly into six groups of control, Cis, Alt, and Cis + Alt groups receiving normal saline for 10 days. All four groups except for the control received Cis (30 mg/kg, i.p.) on day 7, and 6 h later, both the Alt groups received Alt (0.9 mg/kg, i.v.). The animal groups Fund and Fund + Cis received Fund (5 mg/kg, i.p.) for 10 days, and the Fund + Cis group on day 7 received Cis. All the animal groups were euthanized 72 h after the Cis dose. The Fund + Cis group showed significantly increased expression levels of platelet count, retinoid X receptor alpha (RXR-α) and phosphorylated Akt (p-Akt) in addition to decreased levels of urea, blood urea nitrogen (BUN), uric acid, white blood cells (WBCs), red blood cells (RBCs), relative kidney body weight, kidney injury score, glucose, prothrombin (PT), A Disintegrin And Metalloproteinases-10 (ADAM10), extracellular matrix deposition, protease-activated receptor 2 (PAR-2), and fibrinogen expression when compared to the Cis-only group. Meanwhile, the Cis + Alt group showed increased caspase-3 expression in addition to decreased levels of urea, BUN, uric acid, WBCs, RBCs, glucose, platelet count and PT expression with a marked decrease in PAR-2 protein expression compared to the Cis group. The creatinine levels for both the Fund + Cis and Cis + Alt groups were found to be comparable to those of the Cis-only group. The results demonstrate that the coagulation system's activation through the stimulation of PAR-2 and fibrinogen due to Cis-induced ADAM10 protein expression mediated the apoptotic pathway, as indicated by caspase-3 expression through the p-Akt pathway. This is normally accompanied by the loss of RXR-α distal and proximal tubules as lipid droplets. When the animals were pre-treated with the anticoagulant, Fund, the previous deleterious effect was halted while the fibrinolytic agent, Alt, most of the time failed to treat Cis-induced toxicity. 
546 |a EN 
690 |a fondaparinux 
690 |a cisplatin 
690 |a alteplase 
690 |a acute kidney failure 
690 |a apoptosis 
690 |a protein expression 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 16, Iss 7, p 910 (2023) 
787 0 |n https://www.mdpi.com/1424-8247/16/7/910 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/1f634f05d36e43f4906cde7397b5a4c7  |z Connect to this object online.